Kyle Klammer
Family Medicine · Lexington, NENPI 1710334123
Payments from drug & device makers
Across 81 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$356
- AbbVie$216
- Novo Nordisk$199
- Lilly USA, LLC$133
- Astellas Pharma US Inc$85
- Johnson & Johnson$59
- plus $446 from 17 others
What the payments were for
- Food & beverage$1,494100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $356 |
| AbbVie | 14 | $216 |
| Novo Nordisk | 13 | $199 |
| Lilly USA, LLC | 9 | $133 |
| Astellas Pharma US Inc | 5 | $85 |
| Johnson & Johnson | 4 | $59 |
| Alkermes, Inc. | 3 | $56 |
| GSK | 4 | $50 |
| Abbott | 2 | $49 |
| Kerecis Limited | 1 | $47 |
| Amgen | 3 | $40 |
| Pfizer | 3 | $38 |
| Merck | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Organon | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,494 in reported general payments places this provider in the 65th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 21 | $14,538 |
| JardianceEmpagliflozin | 16 | $13,551 |
| XareltoRivaroxaban | 22 | $11,733 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,140 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,794 |
| EliquisApixaban | 11 | $6,373 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 11 | $3,568 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,111 |
| Omeprazole | 68 | $969 |
| Atorvastatin Calcium | 81 | $968 |
| Metoprolol Succinate | 30 | $786 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 11 | $780 |
| Losartan Potassium | 20 | $733 |
| Bumetanide | 14 | $602 |
| Potassium Chloride | 31 | $598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $356 | $22,67933 claims |
| Johnson & JohnsonXarelto | $59 | $11,73322 claims |
| PfizerEliquis, Abrysvo | $38 | $9,94122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lexington
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.